查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496024

全球血液凝固檢驗市場 - 2024 年至 2029 年預測

Global Coagulation Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 123 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計2022年血液凝固檢驗市場規模將達29.7215億美元，預測期內複合年成長率為3.84%，2029年市場總規模將達38688.71億美元。

進行血液凝固檢驗以測試止血系統。此測試通常使用凝血計來測量和評估血栓形成的速度和血栓的速度。血管中形成的血塊可導致心臟病發作、血栓症或栓塞。透過執行這些測試，您可以避免這些不利的結果。

血液和心血管疾病盛行率不斷上升、老年人口不斷增加、照護現場(POC)血液凝固檢驗需求激增，以及配備先進感測器的更快、更易於使用的設備等技術進步正在推動市場發展向前發展做出貢獻。

在過去的十年中，新的凝血分析儀測試的引入和技術的快速進步提高了止血實驗室的品質和效率。肝臟在止血中發揮重要作用，可防止出血和過度凝血。 CN-6000 和 CN-3000 是 Sysmex 最近在 EMEA 地區推出的全自動新一代凝血分析儀。近期發表的CN-6000和CN-3000配備了四項新功能，滿足大批量止血檢測的多樣化需求。

市場促進因素：

  • 人口成長預計將擴大全球血液凝固檢驗市場。

聯合國《世界人口展望》資料顯示，2022年11月世界人口將達80億，這是人類發展的重要里程碑。

中國和印度仍是人口最多的兩個國家，各佔世界人口的近18%，人口均超過10億人。到2023年4月，印度人口預計將增加至1,425,775,850人，超過中國當地人口。

  • 肝病盛行率的增加預計將加速市場成長。

由於肝臟在凝血過程中起著核心作用，因此急性和慢性肝臟疾病與凝血因子和阻礙要素的結合減少、活化劑清除失敗以及血小板數量和品質缺陷有關，由於多種變量，它通常會導致凝血障礙。根據美國肝臟基金會2023年9月的訊息，美國超過1億成年人患有肝病，已有450萬人被診斷出患有肝病。未經治療的肝病可導致肝功能衰竭和癌症，8,000 萬至 1 億成年人可能患有脂肪肝。

  • 此外，根據美國疾病管制與預防中心 2022 年 11 月的訊息，在美國，肝癌每年影響 25,000 名男性和 11,000 名女性，並導致 19,000 人死亡。

此外，根據英國肝臟信託基金的數據，英國每年有超過 10,000 人死於肝病，這一數字在過去 50 年中增加了四倍。 2022年，英格蘭約有9,770人死亡，北愛爾蘭有369人死亡，蘇格蘭有1,237人死亡，里奇有701人死亡，而英國總死亡人數為12,077人。肝病不僅與不平等有關，也與貧窮有關，在蘇格蘭和英格蘭，貧窮地區過早死亡的可能性是富裕地區的四倍。考慮到全球肝病的盛行率，血液凝固檢驗產業預計在預測期內進一步擴大。

  • 隨著醫療保健領域的改善，全球對血液凝固檢驗的需求預計將增加。

凝血分析儀銷售量的增加導致尖端治療設施、實驗室、治療中心和研究機構的數量激增。預計這些變數將在整個預測期內推動市場擴張。血液凝固檢查領域的創新技術進步使檢測方法變得更簡單、更詳細、更準確。

肥胖率的上升需要對血糖值進行廣泛的檢測，對凝血分析儀的需求也顯著增加。由於嚴重的血液相關疾病的治療費用昂貴，心血管和血液疾病患者數量的增加是市場成長的驅動力。老年人口的增加也促進了市場規模的擴大。

市場限制因素：

  • 自動凝血系統的高成本可能會阻礙市場成長。

安裝全自動凝血系統非常昂貴。血液學家以外的工作人員必須經過訓練且有能力。在實驗室之外建立嚴格的品質保證標準更加困難。有關血液凝固檢驗設備的嚴格法規、全自動止血設備的高成本以及對血液測試潛在副作用的擔憂正在阻礙全球市場的成長。此外，先進止血設備的緩慢採用以及對血液凝固檢驗設備的創新和先進應用的認知不足也阻礙了市場的成長，特別是在新興國家。

主要進展

  • 2023 年 5 月 - 西門子 Healthineers 推出 Atellica HEMA 570 和 580 分析儀，這是整合自動化和智慧的下一代血液分析儀。這些分析儀旨在消除工作流程障礙並在大批量血液學檢測中實現高通量。 Atellica HEMA 570 分析儀和 Atellica HEMA 580 分析儀旨在提供直覺的介面和多分析儀自動化連接，幫助醫生可靠地提供關鍵的血液學資訊。傳統上，血液學測試非常複雜、時間敏感，並且需要經驗豐富的工作人員來評估結果。 Atellica HEMA 570 和 580 分析儀旨在消除這些障礙，並實現更快的測試結果和簡化的工作流程。
  • 2023 年 3 月 - Sysmex Corporation 與西門子醫療診斷公司簽訂全球OEM協議，OEM供應止血設備和試劑。該協議允許兩家公司以各自的品牌銷售止血設備和試劑組合，使他們能夠提供更廣泛的產品和服務。此次合作旨在透過為世界各地的實驗室提供有效的解決方案來滿足客戶需求的多樣化。 Sysmex 和西門子 Healthineers 將提供用於凝血障礙測試、術前出血風險管理以及監測接受抗凝血劑治療的患者的止血設備。
  • 2022年7月－Horiba在ISTH2022上參展了Yumizen G系列止血試劑和分析儀。公司推出新一代自動化分析儀Yumizen G800和G1550，以及用於血液凝固檢查的現成試劑。 Yumizen G 的止血產品線支援高品質、經濟高效的出血性疾病篩檢和評估。新一代分析儀旨在滿足中型和重型臨床實驗室的凝血、血友病診斷和監測要求。 Yumizen G 系統每次測試只使用一個比色皿，避免浪費和過度消耗。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球血液凝固檢驗市場：依測試類型

  • 介紹
  • 凝血酶原時間測試
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 纖維蛋白原測試
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 活化凝血時間測試
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 血小板功能檢查
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球血液凝固檢驗市場：依最終使用者分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 診斷中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診治療中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球血液凝固檢驗市場：按地區

  • 介紹
  • 北美洲
    • 按測試類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按測試類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按測試類型
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按測試類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按測試類型
    • 按最終用戶
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Abbott
  • Diagnostica Stago, SAS
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific
  • Enzyme Research Laboratories Ltd
  • Sekisui Medical Co., Ltd.
  • Stago Group
  • Coagulation Sciences LLC
  • RUSNANO Group
  • Universal Biosensors
簡介目錄
Product Code: KSI061611699

The Coagulation Testing market was valued at US$2,972.150 million in 2022 and is expected to increase at a CAGR of 3.84% over the forecast period to reach a total market size of US$3,868.871 million by 2029.

Coagulation tests are conducted to test the hemostasis system. Generally, this test is performed with a coagulometer, which measures and evaluates the rate at which clots form or blood coagulates. A blood clot in a blood vessel can lead to a heart attack, thrombosis, or embolism. By performing these tests, one can avoid these unfavorable outcomes.

A growing prevalence of blood disorders and cardiovascular conditions, an increase in the geriatric population, surging demand for point-of-care (POC) coagulation testing, and technological advancements such as faster and easier-to-use devices with advanced sensors have been contributing to the market growth.

The introduction of new coagulation analyzer tests and rapid advancements in technology have led to an increase in the quality and efficiency of hemostasis laboratories over the past decade. To prevent bleeding and excessive coagulation, the liver plays an essential role in hemostasis. The CN-6000 and CN-3000 are fully automated, next-generation blood coagulation analyzers recently launched by Sysmex in the EMEA region. As part of the CN-6000 and CN-3000, which were recently introduced, four new capabilities have been built to cater to the increasingly diverse needs of high-volume hemostasis testing.

Market Drivers:

  • Rising population is predicted to propel the global market of coagulation testing expansion.

There is an increase in the population of the world which will correlate with increasing healthcare requirement as there will be more incidences of diseases and medical condition including coagulation disorders, according to the United Nations (UN) data on World Population Prospects, the world's population reached 8 billion in November 2022, marking a significant milestone in human development, it expected to reach 9 billion by 2037 while the population is expected to increase by nearly 2 billion in the next 30 years, reaching 9.7 billion in 2050.

China and India remain the two most populous countries, with each representing nearly 18 percent of the world's population both with more than 1 billion individual. In April 2023, India's population was expected to extent to 1,425,775,850 people, surpassing that of mainland China.

  • Increased prevalence of liver disease is expected to surge the market growth.

As the liver is a central player within the clotting process, thus, acute and chronic liver illness regularly leads to coagulation disorders due to a few variables,like decreased amalgamation of clotting and inhibitor factors, an failure to eliminate activated variables, and defects in both amount and quality of platelets. As per American Liver Foundation information from September 2023, more over hundred million U.S. adult individuals suffer from liver disease, with 4.5 million analyzed for it. People with untreated liver disease can lead to liver failure and cancer, with 80-100 million adult people possibly suffering from fatty liver disease and ignorant about it themselves.

  • In addition, as per Centers for Disease and Control and Prevention information of November 2022 Liver cancer influences 25,000 men and 11,000 women within the United States every year, with 19,000 dying from the same.

Moreover, according to British Liver Trust, over 10,000 deaths due to liver disease happen every year within the UK, with a four-fold increment over the past fifty years. In 2022, England had about 9,770 deaths, Northern Ireland had 369, Scotland had 1,237, and Ridges had 701 deaths in total while the UK-wide death number was 12,077. Liver disease is connected to deprivation as well as inequality, with untimely passings being four times higher in deprived regions compared to affluent areas in both Scotland and England. In light of the dominant rate of liver disease globally, the coagulation testing industry will expand at an increasing rate amid the estimate period.

  • Improvements in the Healthcare Sector are anticipated to boost the demand of coagulation testing globally.

The increasing commerce of blood coagulation analyzers have driven to a surge within the advancement of cutting-edge therapeutic facilities, labs, treatment centers, and research organizations. All through the forecasted period, these variables are anticipated to impel market extension. Innovative technological headways in blood coagulation testing have made the method simpler, more detailed, and precise.

Rising obesity rates necessitate extensive testing for blood sugar levels, leading to a massive growth in the demand for blood coagulation analyzers. The increasing population of cardiovascular illnesses and blood disorders is driving market growth, as severe blood-related illnesses can be costly to treat. The geriatric population's growth is also contributing to the market size.

Market Restraints:

  • The high cost of an automated coagulation system could hinder the market growth.

Having a fully automated coagulation system comes at a high cost. Staff members other than hematologists must obtain training and be competent. It is more difficult to establish rigorous quality assurance standards outside the laboratory. Stringent regulations governing coagulation testing devices, the high cost of fully automatic hemostasis equipment, and the concern over the potential side effects of blood testing are inhibiting the growth of the global market. In addition, the slow adoption of advanced hemostasis instruments and the lack of awareness regarding innovative and advanced applications of coagulation test devices are also hampering the market growth, particularly in developing countries

Key Developments:

  • May 2023- Siemens Healthineers introduced the Atellica HEMA 570 and 580 Analyzers, which offer next-gen hematology analyzers with integrated automation and intelligence. These analyzers aim to eliminate workflow barriers and achieve fast throughput in high-volume hematology testing. The Atellica HEMA 570 Analyzer and Atellica HEMA 580 Analyzer are designed to provide intuitive interfaces and multi-analyzer automation connectivity, enabling physicians to deliver critical hematology information reliably. Conventionally, hematology testing is complex and time-sensitive, requiring experienced staff to evaluate results. The Atellica HEMA 570 and 580 Analyzers aim to break down these barriers, enabling faster patient results and improved workflow efficiency.
  • March 2023- Sysmex Corporation and Siemens Healthcare Diagnostics signed a global OEM agreement to supply hemostasis instruments and reagents as OEMs. The agreement allowed both companies to distribute their combined portfolio of hemostasis instruments and reagents under their respective brands, along with their wider products and services. The collaboration aims to diversify customer needs by offering effective solutions to laboratories worldwide. Sysmex and Siemens Healthineers gave hemostasis items utilized in blood clotting disorders testing, preoperative bleeding risk management, and observing patients getting anticoagulant treatment medicines.
  • July 2022- HORIBA Medical displayed its Yumizen G range of hemostasis reagents and analyzers at ISTH 2022 Congress. The company introduced its new generation Yumizen G800 and G1550 automated analyzers, as well as ready-to-use reagents for blood coagulation tests. The Yumizen G hemostasis product range supports high-quality and cost-effective screening and assessment of bleeding disorders. The new-generation analyzers are designed for managing coagulation, thrombophilia diagnostics, and monitoring requirements in clinical laboratories with mid to high workloads. The Yumizen G systems use only one cuvette per test to avoid waste and overconsumption.

Segmentation:

Global Coagulation Testing Market is segmented and analyzed as below:

By Test Type

  • Prothrombin Time Testing
  • Fibrinogen Testing
  • Activated Clotting Time Testing
  • Platelet Function Tests
  • Other

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres
  • Ambulatory Care Centres

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Others
  • Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL COAGULATION TESTING MARKET BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Prothrombin Time Testing
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Fibrinogen Testing
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Activated Clotting Time Testing
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Platelet Function Tests
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Other
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL COAGULATION TESTING MARKET BY END USERS

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Diagnostic Centres
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Ambulatory Care Centres
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL COAGULATION TESTING MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Test Type
    • 7.2.2. By End Users
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Test Type
    • 7.3.2. By End Users
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Test Type
    • 7.4.2. By End Users
    • 7.4.3. By Country
      • 7.4.3.1. UK
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Others
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Test Type
    • 7.5.2. By End Users
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Israel
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
      • 7.5.3.4. Others
        • 7.5.3.4.1. Market Opportunities and Trends
        • 7.5.3.4.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Test Type
    • 7.6.2. By End Users
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. India
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. South Korea
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Taiwan
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Thailand
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Indonesia
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Japan
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Abbott
  • 9.2. Diagnostica Stago, S.A.S.
  • 9.3. F. Hoffmann-La Roche Ltd
  • 9.4. Thermo Fisher Scientific
  • 9.5. Enzyme Research Laboratories Ltd
  • 9.6. Sekisui Medical Co., Ltd.
  • 9.7. Stago Group
  • 9.8. Coagulation Sciences LLC
  • 9.9. RUSNANO Group
  • 9.10. Universal Biosensors